Tiotropium Inhalation Solution for Nebulization
The present invention relates to a sterile pharmaceutical composition comprising tiotropium or a pharmaceutically acceptable salt thereof, for inhalation via nebulization to a subject (e.g. a human). The invention also relates to a process for preparing the pharmaceutical composition and its use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) in a subject.
1 . An benzalkonium chloride-free, EDTA-free pharmaceutical composition comprising:
i) 0.0007-0.00088 wt. % tiotropium;
ii) 0.08-0.2 wt. % sodium citrate;
iii) 0.2-0.6 wt. % citric acid;
iv) 0.6-0.9 wt. % sodium chloride; and
v) 97-99.2 wt. % water.
2 . The composition of claim 1 , wherein the composition is complexing agent-free.
3 . The composition of claim 2 , wherein the composition is preservative-free.
4 . The composition of claim 3 , wherein a 2 mL dose of the preservative-free, complexing agent-free pharmaceutical composition containing 14-17.6 mcg of tiotropium dispensed through a nebulizer is bioequivalent to a dose of a tiotropium solution containing 5 mcg of tiotropium dispensed through an inhaler, the tiotropium solution comprising water, tiotropium bromide monohydrate, edetate disodium, benzalkonium chloride and hydrochloric acid.
5 . The composition of claim 4 , wherein the nebulized dose of the pharmaceutical composition is bioequivalent when compared to:
(a) an AUC of tiotropium of the inhaler-dispensed dose of the tiotropium solution; and
(b) a C max of tiotropium of the inhaler-dispensed dose of the tiotropium solution.
6 . The composition of claim 4 , wherein the nebulized dose of the pharmaceutical composition provides:
(a) an AUC of tiotropium in the range of 80-125% of an AUC of tiotropium of the inhaler-dispensed dose of the tiotropium solution; and
(b) a C max of tiotropium in the range of 80-125% of a C max of tiotropium of the inhaler-dispensed dose of the tiotropium solution.
7 . The composition of claim 4 , wherein the nebulized dose of the pharmaceutical composition provides: (a) an AUC of tiotropium of 25.7-40.2 pg-h/mL; and (b) a C max of tiotropium of 12-19.5 pg/mL.
8 . The composition of claim 4 , wherein the nebulized dose of the pharmaceutical composition is bioequivalent when compared to: an improvement in trough FEV 1 compared to placebo of the inhaler-dispensed dose of the tiotropium solution.
9 . The composition of claim 4 , wherein the nebulized dose is nebulized in an air-driven jet nebulizer.
10 . The composition of claim 1 , wherein the concentration of the sodium citrate is in the range of 0.1-0.11 wt. %.
11 . The composition of claim 10 , wherein the concentration of citric acid is 0.4 wt. %.
12 . The composition of claim 11 , wherein the concentration of sodium chloride is 0.8 wt. %.
13 . The composition of claim 12 , wherein the composition is exclusive of additional excipients.
14 . A pharmaceutical product, comprising:
i) a container having a volume in the range of 0.25-6 mL and;
ii) a volume of a benzalkonium chloride-free, EDTA-free complexing agent-free pharmaceutical composition contained in the container, the pharmaceutical composition comprising:
a) tiotropium;
b) 0.08-0.2 wt. % sodium citrate;
c) 0.2-0.6 wt. % citric acid; and
d) at least 97 wt. % water,
the pharmaceutical product administrable by a nebulizer to provide a nebulized dose of the pharmaceutical composition that is bioequivalent to an inhaler-administered dose of a tiotropium solution.
15 . The product of claim 14 , wherein the volume of the pharmaceutical composition is 2 mL.
16 . The product of claim 14 , which contains 14-17.6 mcg of tiotropium.
17 . A method of treating a patient, comprising administering a plurality of the pharmaceutical product of claim 14 according to a prescribed treatment schedule to achieve an improvement in trough FEV 1 of at least 10% or at least 100 mL above placebo.
18 . The method of claim 17 , wherein the prescribed treatment schedule extends for at least 48 weeks and the improvement is maintained from after 1 week of the prescribed treatment until the end of the at least 48 weeks.
19 . A method of treating a human COPD patient, comprising administering, once daily, a unit dose of a benzalkonium chloride-free, EDTA-free pharmaceutical composition, the composition comprising:
i) 0.0007-0.00088 wt. % tiotropium;
ii) 0.08-0.2 wt. % sodium citrate;
iii) 0.2-0.6 wt. % citric acid;
iv) 0.6-0.9 wt. % sodium chloride; and
v) 97-99.2 wt. % water,
wherein a 2 mL dose of the benzalkonium chloride-free, EDTA-free pharmaceutical composition containing 14-17.6 mcg of tiotropium dispensed through a nebulizer is bioequivalent to a dose of a tiotropium solution containing 5 mcg of tiotropium dispensed through an inhaler, the tiotropium solution comprising water, tiotropium bromide monohydrate, edetate disodium, benzalkonium chloride and hydrochloric acid.
20 . The method of claim 19 , wherein the nebulized dose of the pharmaceutical composition provides an improvement in trough FEV 1 in a patient that is in the range of 80-125% of an improvement in trough FEV 1 of the inhaler-dispensed dose of the tiotropium solution.